Business Context and Reporting Period
Company: ImmuCell Corporation (ICCC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: ImmuCell develops, manufactures, and sells products for the dairy and beef industries. Its primary revenue-generating product is First Defense (a vaccine for bovine enteritis). The company is heavily investing in the development of Mast Out, a novel treatment for mastitis in dairy cows, which is currently in the regulatory approval phase with the FDA.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Total Revenues | $874,133 | $3,265,527 |
| Net Loss | $(197,116) | $(256,821) |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.09) |
| Cash and Cash Equivalents | $2,829,129 | $2,829,129 (Balance Sheet) |
| Short-Term Investments | $2,229,000 | $2,229,000 (Balance Sheet) |
| Total Current Assets | $7,076,372 | $7,076,372 (Balance Sheet) |
| Total Liabilities | $1,418,396 | $1,418,396 (Balance Sheet) |
| Bank Debt (Current + Long-Term) | $996,536 | $996,536 (Balance Sheet) |
| Net Cash Used in Operating Activities | N/A | $(387,241) |
| Gross Margin (Product Sales) | 41% | 53% |
Material Changes vs. Prior Period
- Revenue Decline: Product sales decreased 14% ($137,000) in the three-month period and 6% ($208,000) in the nine-month period compared to 2009. Management attributes this to the global economic downturn affecting the dairy industry and a lack of order backlog in 2010 compared to a $287,000 backlog in Q3 2009.
- Increased Losses: Net loss widened significantly to $197,000 for the quarter (vs. $19,000 in 2009) and $257,000 for the nine-month period (vs. $201,000 in 2009). This is driven by increased sales and marketing expenses and continued investment in product development.
- Expense Increases: Sales and marketing expenses rose 83% in the quarter and 48% for the nine-month period due to strategic hiring. Product development expenses decreased 16% year-over-year for the nine-month period but are expected to rise significantly in Q4 2010 and 2011.
- Debt Financing: In August 2010, the company secured approximately $2.1 million in credit facilities (including a $1 million mortgage and $600,000 term loan) to fund operations and development. This resulted in a new long-term liability of approximately $994,000 on the balance sheet.
- Liquidity: Despite operating cash outflows, total cash and short-term investments increased to $5.06 million due to debt proceeds and investment maturities.
Guidance, Outlook, and Risks
- Outlook: Management projects a net loss for the remainder of 2010 and an increased net loss for 2011 due to the capital-intensive development of Mast Out. The company expects to return to profitability in 2012, contingent on the commercial launch of Mast Out or sustained sales of existing products.
- Regulatory Timeline: The company expects to submit the Chemistry, Manufacturing, and Controls (CMC) section of the New Animal Drug Application (NADA) for Mast Out in Q1 2011. FDA approval is tentatively targeted for mid-2012.
- Key Risks:
- Regulatory Approval: No assurance that Mast Out will receive FDA approval, particularly regarding the "zero milk discard" claim which is a key competitive advantage.
- Market Conditions: The dairy industry faces economic pressure from low milk prices and high feed costs, which may limit customer spending.
- Customer Concentration: Three distributors accounted for 48% of product sales in the first nine months of 2010.
- Capital Needs: Additional financing (likely from a partner) will be required in 2012 to fund commercial batch production for a full market launch.
Investor Verification Checklist
- Debt Covenants: Verify the specific terms and covenants of the new $2.1 million credit facility with TD Bank, N.A., particularly regarding interest rates and repayment schedules.
- Regulatory Milestones: Monitor the status of the Mast Out NADA submissions, specifically the CMC and Human Food Safety sections, as delays could push the 2012 launch date.
- Cash Burn Rate: Assess whether the current cash balance ($5.06 million) and gross margins are sufficient to cover the projected increased R&D spend in late 2010 and 2011 without further dilution or debt.
- Customer Concentration: Review the stability of the top three distributors, which represent nearly half of the company's revenue.
- Manufacturing Capacity: Confirm the progress of the manufacturing agreements with Lonza and Norbrook Laboratories, as these are critical for the commercial scale-up of Mast Out.